Niche Modulation of IGF-1R Signaling: Its Role in Stem Cell Pluripotency, Cancer Reprogramming, and Therapeutic Applications.
IGF-1R
cancer stemness
extracellular matrix
hypoxia
inflammation
niche
stem cells
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2020
2020
Historique:
received:
04
11
2020
accepted:
15
12
2020
entrez:
29
1
2021
pubmed:
30
1
2021
medline:
30
1
2021
Statut:
epublish
Résumé
Stem cells work with their niches harmoniously during development. This concept has been extended to cancer pathology for cancer stem cells (CSCs) or cancer reprogramming. IGF-1R, a classical survival signaling, has been shown to regulate stem cell pluripotency, CSCs, or cancer reprogramming. The mechanism underlying such cell fate determination is unclear. We propose the determination is due to different niches in embryo development and tumor malignancy which modulate the consequences of IGF-1R signaling. Here we highlight the modulations of these niche parameters (hypoxia, inflammation, extracellular matrix), and the targeted stem cells (embryonic stem cells, germline stem cells, and mesenchymal stem cells) and CSCs, with relevance to cancer reprogramming. We organize known interaction between IGF-1R signaling and distinct niches in the double-sided cell fate with emerging trends highlighted. Based on these new insights, we propose that, through targeting IGF-1R signaling modulation, stem cell therapy and cancer stemness treatment can be further explored.
Identifiants
pubmed: 33511137
doi: 10.3389/fcell.2020.625943
pmc: PMC7835526
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
625943Informations de copyright
Copyright © 2021 Chen, Kuo, Chuong and Huang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Sci Signal. 2010 Feb 09;3(108):ra10
pubmed: 20145208
Stem Cells. 2010 Jan;28(1):57-63
pubmed: 19890980
Growth Factors. 2009 Dec;27(6):425-37
pubmed: 19919531
Cancers (Basel). 2019 Mar 11;11(3):
pubmed: 30862050
Endocrinology. 2004 Feb;145(2):620-6
pubmed: 14605000
Oncogene. 2015 Apr 23;34(17):2227-38
pubmed: 24909165
Clin Cancer Res. 2015 Jan 1;21(1):201-10
pubmed: 25564572
Int J Mol Med. 2017 Dec;40(6):1860-1868
pubmed: 29039467
J Biol Chem. 2016 Apr 8;291(15):8140-9
pubmed: 26865633
Mol Cancer Res. 2013 Nov;11(11):1303-13
pubmed: 23928059
Drug Des Devel Ther. 2018 Sep 11;12:2887-2896
pubmed: 30254418
Folia Histochem Cytobiol. 2016;54(1):14-24
pubmed: 27044590
Cell. 2008 Feb 22;132(4):598-611
pubmed: 18295578
Growth Factors. 2015;33(4):275-81
pubmed: 26340107
J Biol Chem. 2011 Oct 7;286(40):34712-21
pubmed: 21840990
Cells Tissues Organs. 2018;205(5-6):350-371
pubmed: 30273927
PLoS One. 2015 Jul 14;10(7):e0133152
pubmed: 26173023
J Clin Endocrinol Metab. 2007 Dec;92(12):4529-35
pubmed: 17986643
Mol Cell Endocrinol. 1996 Apr 19;118(1-2):1-8
pubmed: 8735585
Expert Opin Investig Drugs. 2019 Dec;28(12):1101-1112
pubmed: 31731883
Differentiation. 2008 May;76(5):488-94
pubmed: 18021255
Cancer Res. 2013 May 15;73(10):3181-9
pubmed: 23539445
J Biol Chem. 2012 Jan 20;287(4):2766-76
pubmed: 22128190
Nature. 2001 May 17;411(6835):349-54
pubmed: 11357142
Breast Cancer Res. 2013 May 12;15(3):R39
pubmed: 23663564
Cancer Res. 2018 Jul 1;78(13):3497-3509
pubmed: 29735545
Cell Physiol Biochem. 2018;47(1):39-53
pubmed: 29763915
Mol Med Rep. 2018 Mar;17(3):4681-4687
pubmed: 29344668
Oncotarget. 2017 Sep 23;8(49):86592-86603
pubmed: 29156819
Oxid Med Cell Longev. 2019 Dec 5;2019:7954657
pubmed: 31885817
Exp Mol Med. 2018 Apr 13;50(4):25
pubmed: 29650947
Mol Hum Reprod. 2014 Jun;20(6):526-37
pubmed: 24598112
Cell Stem Cell. 2010 Aug 6;7(2):150-61
pubmed: 20682444
Theranostics. 2017 Apr 10;7(6):1598-1611
pubmed: 28529639
Science. 2005 Oct 7;310(5745):68-71
pubmed: 16210527
Exp Eye Res. 2010 Mar;90(3):374-5
pubmed: 19799900
Cancer Res. 2017 Aug 1;77(15):4014-4025
pubmed: 28619711
Nat Rev Mol Cell Biol. 2008 Apr;9(4):285-96
pubmed: 18285802
PLoS One. 2017 Dec 22;12(12):e0190159
pubmed: 29272313
Oncogene. 2016 May 19;35(20):2634-44
pubmed: 26364612
Development. 2018 Aug 1;145(15):
pubmed: 30068689
Cardiovasc Res. 2016 Aug 1;111(3):184-93
pubmed: 27013635
Nat Rev Cancer. 2005 Nov;5(11):899-904
pubmed: 16327766
J Clin Endocrinol Metab. 2004 Jul;89(7):3543-53
pubmed: 15240644
J Cell Physiol. 2017 Oct;232(10):2722-2730
pubmed: 28112398
Oncogene. 2010 Apr 29;29(17):2488-98
pubmed: 20154720
F1000Res. 2016 Apr 19;5:
pubmed: 27134739
J Cell Mol Med. 2017 Dec;21(12):3467-3480
pubmed: 28661035
Nat Rev Genet. 2007 Apr;8(4):263-71
pubmed: 17363975
PLoS One. 2016 Feb 26;11(2):e0149897
pubmed: 26919045
Mol Med Rep. 2017 Jul;16(1):787-793
pubmed: 28560388
BMC Cancer. 2015 Apr 04;15:223
pubmed: 25886138
Nat Med. 2011 Mar;17(3):313-9
pubmed: 21386835
Cancer Res. 2009 Mar 1;69(5):1951-7
pubmed: 19244128
Cell Mol Life Sci. 2014 Jul;71(13):2403-27
pubmed: 24276851
FASEB J. 2009 Jul;23(7):2076-87
pubmed: 19246485
Eur J Cancer. 2012 Nov;48(16):3027-35
pubmed: 22682017
Am J Respir Cell Mol Biol. 2016 Dec;55(6):779-791
pubmed: 27438786
FASEB J. 2004 Sep;18(12):1456-8
pubmed: 15247143
Knee Surg Sports Traumatol Arthrosc. 2014 Nov;22(11):2867-73
pubmed: 23736255
Cancer Lett. 2016 Feb 28;371(2):171-81
pubmed: 26655273
Stem Cells. 2015 May;33(5):1480-9
pubmed: 25532472
Proc Natl Acad Sci U S A. 2015 Apr 14;112(15):4678-83
pubmed: 25825734
Stem Cell Reports. 2018 Feb 13;10(2):524-537
pubmed: 29307582
Stem Cells. 2012 May;30(5):876-87
pubmed: 22311737
PLoS One. 2016 Aug 03;11(8):e0159912
pubmed: 27487118
Mol Cell Endocrinol. 2017 Sep 5;452:1-14
pubmed: 28435049
Exp Neurobiol. 2018 Dec;27(6):489-507
pubmed: 30636901
Nat Med. 2012 Jul;18(7):1095-101
pubmed: 22729283
J Cell Biochem. 2010 Jan 1;109(1):1-6
pubmed: 19899110
J Physiol. 2016 Sep 1;594(17):4837-47
pubmed: 27581568
Biochem Biophys Res Commun. 2017 Jan 1;482(1):35-42
pubmed: 27836546
Oncogene. 2014 Jul 24;33(30):3908-17
pubmed: 24013232
Blood. 2007 Dec 1;110(12):4111-9
pubmed: 17761519
Cell Cycle. 2011 Jul 15;10(14):2331-8
pubmed: 21720213
Nat Rev Cancer. 2014 May;14(5):329-41
pubmed: 24722429
Mol Endocrinol. 2015 Nov;29(11):1549-57
pubmed: 26366975
J Am Heart Assoc. 2015 Sep 11;4(9):e002104
pubmed: 26363004
Oncotarget. 2016 Jul 5;7(27):42288-42302
pubmed: 27275536
PLoS One. 2013 Sep 04;8(9):e72435
pubmed: 24023739
Nature. 2001 Nov 1;414(6859):105-11
pubmed: 11689955
Int J Nanomedicine. 2019 Apr 23;14:2847-2859
pubmed: 31114198
Sci Rep. 2018 Jul 16;8(1):10711
pubmed: 30013043
Br J Cancer. 2017 Dec 5;117(12):1777-1786
pubmed: 29123263
Nat Commun. 2014 Mar 25;5:3472
pubmed: 24668028
Brain Res. 2004 Dec 24;1030(1):19-27
pubmed: 15567334
Biochim Biophys Acta. 2013 Feb;1830(2):2280-96
pubmed: 22959078
Nature. 2007 Aug 30;448(7157):1015-21
pubmed: 17625568
J Exp Clin Cancer Res. 2019 Nov 26;38(1):474
pubmed: 31771617
Gut. 2017 Mar;66(3):530-540
pubmed: 26658144
Cancer Res. 2016 Feb 15;76(4):974-83
pubmed: 26837769
Cytokine Growth Factor Rev. 2017 Apr;34:67-72
pubmed: 28190785
Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):E12063-E12072
pubmed: 30509997
J Cell Physiol. 2019 Apr;234(4):4068-4080
pubmed: 30146725
EMBO Rep. 2012 Mar 01;13(3):244-50
pubmed: 22261717
J Cell Physiol. 2012 Jul;227(7):2947-52
pubmed: 21959795
Nature. 2016 Nov 24;539(7630):570-574
pubmed: 27820945
Br J Pharmacol. 2008 Jun;154(3):557-68
pubmed: 18500379
J Biol Chem. 2004 Feb 6;279(6):4269-77
pubmed: 14645245
Mol Cancer. 2017 Feb 1;16(1):29
pubmed: 28148257
Sci Rep. 2016 Sep 02;6:32595
pubmed: 27586516
Gastroenterology. 2016 Dec;151(6):1192-1205
pubmed: 27614046
Cancer Res. 2010 Aug 15;70(16):6412-9
pubmed: 20710042
J Biol Chem. 2013 Jul 5;288(27):19593-603
pubmed: 23696648
Sci Rep. 2017 May 19;7(1):2164
pubmed: 28526827